Drug intelligence / Profile preview

Inactivated Poliovirus Vaccine (Salk-based)

Development stage: Unknown
Lead developer: Jonas Salk
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

Inactivated Poliovirus Vaccine (Salk-based), also known as cIPV or Salk vaccine, is a pharmaceutical vaccine developed by Dr. Jonas Salk in 1955. It consists of inactivated (killed) poliovirus strains of all three poliovirus types (1, 2, and 3). The vaccine works by stimulating the body's immune system to produce antibodies against the poliovirus, which prevents the virus from spreading to the central nervous system and protects against paralytic poliomyelitis. It is administered via intramuscular injection.

Other names: Inactivated Poliomyelitis Vaccine (Salk Vaccine)

Beyond the preview

Go deeper on Inactivated Poliovirus Vaccine (Salk-based).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactivated Poliovirus Vaccine (Salk-based).

Explore the full profile